SUMMARY
During ASH 2024, the role of autologous stem cell transplantation (ASCT) for patients with mantle cell lymphoma (MCL) was questioned in the TRIANGLE and ECOG-ACRIN EA4151 trials. In addition, the ENRICH trial evaluated the efficacy and safety of a chemotherapy-free regimen for older patients with untreated MCL. Regarding diffuse large-B-cell lymphoma (DLBCL), extended follow-up data of the POLARIX trial were presented, comparing R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone) to pola-R-CHP (polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin and prednisone) as first-line treatment. Also, the addition of the bispecific antibody glofitamab to R-CHOP or pola-R-CHP was evaluated in the COALITION trial, including younger patients with high-risk DLBCL. Finally, interim results of the DALY II trial were presented, assessing the feasibility, safety and efficacy of chimeric antigen receptor T (CAR T)-cell therapy with zamtocabtagene autoleucel (zamto-cel) for relapsed/refractory (R/R) DLBCL.
(BELG J HEMATOL 2025;16(1):41–6)
